{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00015",
      "entity_text" : "Sarcoma",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P15056",
      "entity_text" : "BRAF",
      "features" : [ {
        "to_base" : "V",
        "site" : 600,
        "feature_type" : "mutation",
        "evidence" : "V600E"
      } ],
      "entity_type" : "protein"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "It could be hypothesized that BRAF V600E inhibitors like vemurafenib could paradoxically activate BRAF wild-type and RAS (RAt Sarcoma) pathway in other cells and induce vasculitis or other inflammatory reactions.",
  "reading_complete" : "2020-07-28T13:04:44Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T13:02:09Z",
  "trigger" : "activate",
  "evidence" : [ "BRAF V600E  inhibitors like vemurafenib could paradoxically activate BRAF wild-type and RAS (RAt Sarcoma" ],
  "pmc_id" : "5120889",
  "score" : 0
}